



A.



B.



C.





FIG. 1

A.



B.



C.



FIG. 2




FIG. 3

Tail Vein Injections







FIG. 4




DTBP




diimide activated crosslinker




diimide activated crosslinker with additional positive charge




di-NHS ester activated crosslinker with additional positive charge




di-NHS ester activated crosslinker with no additional positive charge



dithiosalicylic acid



Dithionicotinic acid



Ellman's reagent

FIG. 5

**Tail Vein Delivery
(Non-cleavable polymers)**




FIG. 6

Itravascular gene delivery




FIG. 7

Immunofluorescent staining (red) for endothelial cells (CD31)




FIG. 8